Discover A Hidden Gem In The Booming Cell Therapy Market…

See why now could be the best time to start your research on Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)

Price Targets




Bonus: $5.00 (+159.07%) Potential support at 1.74


Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

7 Reasons to Focus Now on Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) Could See Significant Upside Potential In 2023.

The cell therapy market is booming! From a value of $10.35 billion in 2021, it's projected to skyrocket to $60.67 billion by 2030.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)'s SNAP-CAR Technology Platform Showcased for Advancement Efforts in Antigen Receptor Design.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is positioned to expand its cell therapy assets with opportunity to acquire allogeneic immuno-oncology NK platform.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is positioned to expand oncology pipeline with opportunity to increase ownership in VyGen-Bio assets.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)'s SNAP-CAR technology featured in peer-reviewed article.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) and the University of Pittsburgh join forces to prioritize the development of Universal CAR T cell therapy for solid tumors.

Coeptis Therapeutics appoints Brian Cogley as Chief Financial Officer.

Company Information

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic.

Cell Therapy Market Size

The global cell therapy market has witnessed remarkable growth in recent years, fueled by various factors contributing to its expansion. Valued at US$ 10.35 billion in 2021, the market is projected to reach US$ 60.67 billion by 2030, exhibiting a robust compound annual growth rate (CAGR) of 21.72% from 2022 to 2030. The increasing prevalence of chronic disorders and advancements in technology are key drivers propelling this growth.



With a float of roughly 11M free shares, a little bit of investor interest could send this soaring!

Recent break and test of long-term resistance level now acting as support

Moving averages are stacking bullish, crossed to the upside and separating

We have been seeing sustained volume after April and that's exactly the kind of action we want to see on a micro-float stock after a recent break and test of a strong support level.


Ideally, we would see a strong open and sustain a volume push over 30k. We need to see it hold this local support level and maintain this bullish sentiment in doing so. Once we see that, we should see some nice confirmations and can ride the wave.


Target #1: $2.38(+23.32%)

Target #2: $2.67 (+38.34%)

Target #3: $3.00 (+55.44%)

Bonus: $5.00 (+159.07%)

Support: $1.74



The Cell Therapy Market is Booming! From a Value of $10.3B in 2021, it's Projected to Skyrocket to Over $60B by 2030.

The global cell therapy market has witnessed remarkable growth in recent years, fueled by various factors contributing to its expansion. Valued at US$ 10.35 billion in 2021, the market is projected to reach US$ 60.67 billion by 2030, exhibiting a robust compound annual growth rate (CAGR) of 21.72% from 2022 to 2030. The increasing prevalence of chronic disorders and advancements in technology are key drivers propelling this growth.

The surge in chronic disorders worldwide has played a significant role in the growth of the global cell therapy market. The prevalence of diseases such as diabetes has notably contributed to this trend. According to the International Diabetes Federation Diabetes Atlas, there were approximately 573 million people globally with diabetes in 2021, and this number is expected to increase to 643 million by 2030 and 783 million by 2045. As a result, there is a growing need for innovative therapies like cell therapy to address these chronic conditions.

The adoption of innovative and advanced technologies is driving the expansion of the global cell therapy market. Ongoing research and development efforts have paved the way for groundbreaking advancements in the field. With over 900 companies worldwide actively working on advanced therapeutics and approximately 1,000 cell or gene therapy clinical studies in progress, the cell therapy market is witnessing rapid growth. Experts predict that up to 60 new cell therapies could be developed in the coming years, offering potential treatments for a wide range of conditions.

While the global cell therapy market shows promising growth, there are challenges that need to be addressed. The high cost of cell therapies remains a significant obstacle, limiting accessibility for patients. Additionally, a shortage of skilled professionals in the field poses a challenge to the widespread adoption of cell therapy. However, ongoing advancements, research, and development efforts aim to address these challenges and pave the way for future growth in the market.

One emerging company in the cell therapy market to keep an eye on is Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP). (2) With its focus on advancing cell therapy platforms for cancer treatment and a commitment to innovation, Coeptis Therapeutics is positioning itself to potentially be a key player in this massive industry.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)'s SNAP-CAR Technology Platform Showcased for Advancements in Antigen Receptor Design

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) continues to make strides in the biopharmaceutical industry with its innovative SNAP-CAR technology platform. A recent milestone for the company comes in the form of a peer-reviewed article published in the esteemed scientific journal Nature Communications, showcasing the potential of Coeptis’ SNAP-CAR technology to revolutionize chimeric antigen receptor (CAR) T cell therapies for various cancers and indications.

Titled “Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting,” the article explores significant advancements in antigen receptor design and the development of universal receptor systems utilizing covalent chemistry for diverse programming of cell behaviors. Coeptis’ SNAP-CAR platform, designed as a powerful adaptor strategy, is being developed to enable fully programmable targeting of engineered cells to multiple antigens.

Coeptis’ pre-clinical development efforts thus far, , conducted using in vitro and in vivo models, has supported the adaptability and programmability of SNAP-CAR as a therapeutic approach. By leveraging self-labeling enzyme chemistry, SNAP-CAR is envisioned to allow researchers to rapidly screen CAR and synNotch antibody candidates and activate cellular programs in response to highly specific antibody-antigen interactions. This breakthrough technology would pave the way for novel cell therapies across a wide range of cancers, including hematologic and solid tumors.

Coeptis Therapeutics takes pride in its collaboration with the University of Pittsburgh, where SNAP-CAR was originally licensed, and commends the groundbreaking work led by Dr. Jason Lohmueller and his team.

Coeptis Therapeutics is excited about the potential for SNAP-CAR to represent a major advancement in programmable antigen targeting. With its indicated ability to enhance the targeting capabilities of CAR T cells, SNAP-CAR is viewed by Coeptis Therapeutics to present a promising therapeutic platform for a variety of cancer indications. The company is actively exploring the application of SNAP-CAR technology in addressing HER2-expressing cancers as its potential first-in-human clinical development program.

The publication of this research in Nature Communications not only showcases the innovative work being carried out by Coeptis Therapeutics but also emphasizes the advancements being made generally in the field of cancer immunotherapy. Coeptis remains committed to harnessing the potential of SNAP-CAR and driving the development of highly adaptable and programmable cell therapies with the primary goal of improving patient outcomes.



Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is Positioned to Expand Cell Therapy Assets with Opportunity to Acquire of Allogeneic Immuno-Oncology NK Platform

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced a significant development in its mission to advance innovative cell therapy platforms for cancer treatment. The company has entered into a binding term sheet with Deverra Therapeutics, Inc., securing its exclusive rights to negotiate the acquisition and/or license of certain key assets related to Deverra Therapeutics’ allogeneic stem cell expansion and directed differentiation platform.

This proposed transaction, if closed, would provide Coeptis with exclusive rights to two FDA-approved Investigational New Drug (IND) applications and two Phase 1 clinical trials involving DVX201, an unmodified natural killer (NK) cell therapy. These clinical programs focus on relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), as well as patients hospitalized with respiratory viral infections.

Beyond the clinical assets, the transaction would provide Coeptis with access to a scalable allogeneic cellular immunotherapy platform. This platform aims to generate and deliver off-the-shelf cell therapies, removing the need for HLA matching and offering cost-effective treatment options for a broad patient population.

Recognizing the transformative potential of the allogeneic NK platform, Coeptis Therapeutics would aim to combine its expertise with the advanced technology from Deverra Therapeutics to accelerate the development of innovative cell therapies targeting hematologic and solid tumors.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed excitement about the proposed transaction and the potential for expanding the company’s research and development capabilities. He highlighted the opportunity to leverage the allogeneic cell therapy platform to develop novel approaches to combination cellular immunotherapy and explore the application of SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells.

While the proposed transaction is subject to confirmatory due diligence, negotiation of definitive documentation, and other closing conditions, including third-party approvals, Coeptis Therapeutics is committed to maximizing the value of its product portfolio through strategic partnerships and expanding its offerings in the field of cancer treatment.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is Positioned to Expand Oncology Pipeline with Opportunity to Increase Ownership in VyGen-Bio Assets

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has taken a significant step forward in its mission to develop cutting-edge cell therapy platforms for cancer treatment. The company has secured exclusive rights to negotiate the acquisition of VyGen-Bio, Inc. or its assets, an opportunity that Coeptis believes holds great promise for enhancing its oncology pipeline and advancing transformative cell and gene therapies.

VyGen-Bio’s GEAR™ platform, discovered by scientists at the prestigious Karolinska Institutet, offers tremendous potential for cell engineering approaches in cancer treatment. Coeptis aims to leverage this potential acquisition to expand its capabilities and accelerate the development of innovative cell therapies.

Coeptis Therapeutics and VyGen-Bio are already collaborating on CD38-GEAR-NK, a natural killer (NK) cell therapy designed to target CD38+ cancers, particularly multiple myeloma. Additionally, they are jointly working on CD38-Diagnostic, an in vitro diagnostic tool that identifies suitable cancer patients for anti-CD38 monoclonal antibody (mAb) therapy.

By leveraging the GEAR platform, Coeptis envisions the improvement of existing cancer therapies and the expansion of treatment applications to new indications. GEAR’s unique cell engineering approach preserves cell integrity, fitness, and function while ensuring compatibility with co-administered monoclonal antibodies (mAbs), paving the way for innovative treatment strategies.

Coeptis is dedicated to developing first-in-class allogeneic cell therapies that effectively target and treat a wide range of life-threatening disorders, providing cost-effective and accessible solutions.

Coeptis Therapeutics remains committed to maximizing the value of its product portfolio through strategic partnerships and collaborations. The potential acquisition of VyGen-Bio and the transformative GEAR platform exemplify the company’s unwavering dedication to advancing cancer treatment boundaries and improving patient outcomes.



Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)'s SNAP-CAR Technology Featured in Peer-Reviewed Article.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) and its SNAP-CAR technology has been featured in a recent peer-reviewed article published in the Journal of Translational Medicine. The article focuses on the latest developments in CAR T cell technologies designed to enhance the outcomes of cell therapy and minimize associated risks.

SNAP-CAR, a multi-antigen chimeric antigen receptor T cell (CAR T) technology that is being developed by Coeptis Therapeutics, is viewed to have the potential offer a powerful approach to address different cancer indications, including hematologic and solid tumors. In this article, the authors describe SNAP-CAR as an “up-and-coming” technology that covalently links therapeutic monoclonal antibodies (mAbs) to universal CAR receptors, providing a highly programmable platform for precise targeting of engineered cells to multiple antigens.

Dave Mehalick, the President and CEO of Coeptis Therapeutics, expressed his satisfaction with the recognition of SNAP-CAR in this esteemed scientific journal. He highlighted the potential of the technology to enable the development of cell therapies for a wide range of cancers, including hematologic and solid tumors. Coeptis Therapeutics’ collaboration with the University of Pittsburgh in advancing SNAP-CAR showcases their commitment to driving innovation in the field of cell therapy.

SNAP-CAR’s ability to adapt to different cancer indications and its programmability offers researchers a valuable tool for advancing precision medicine. By covalently linking therapeutic monoclonal antibodies to CAR receptors, SNAP-CAR is designed to overcome limitations associated with a lower affinity of soluble adaptors, presenting a promising strategy for improved safety, efficacy, and flexibility in CAR T cell therapy.

The inclusion of SNAP-CAR in this peer-reviewed article solidifies Coeptis Therapeutics’ position as a leading innovator in the development of cell therapy platforms for cancer treatment. With their continued focus on maximizing the potential of SNAP-CAR, Coeptis Therapeutics aims to transform the landscape of cancer therapies and improve patient outcomes.

As the field of cell therapy continues to evolve, Coeptis Therapeutics remains dedicated to pushing the boundaries of innovation and driving advancements in cancer treatment. The recognition of SNAP-CAR in this prestigious scientific journal highlights the company’s commitment to revolutionizing cancer therapeutics and bringing hope to patients worldwide.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) and University of Pittsburgh Join Forces to Accelerate Development of Universal CAR T Cell Therapy for Solid Tumors

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has achieved a significant milestone in the development of its SNAP-CAR technology platform through a sponsored research agreement with the University of Pittsburgh. This collaboration marks a crucial step towards advancing the pre-clinical development of SNAP-CAR T cells, with a specific focus on targeting HER2-positive cancers. Additionally, the partnership aims to explore opportunities to expand the application of SNAP-CAR in the field of oncology.

Under the terms of the agreement, the University of Pittsburgh will conduct essential pre-clinical research to support the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR T cells. Dr. Jason Lohmueller and Dr. Alexander Deiters, principal investigators, will lead the research team in close collaboration with Coeptis Therapeutics’ contract research organization partner, IQVIA. Together, they will develop a treatment strategy for ovarian cancer and identify a lead candidate for future clinical development.

SNAP-CAR, a versatile multi-antigen chimeric antigen receptor T cell (CAR T) technology, has demonstrated great promise in adapting to various cancer indications. This collaboration with the University of Pittsburgh is expected to expedite the development of SNAP-CAR as a “universal” CAR T cell therapy platform, with the potential to overcome existing limitations.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed his enthusiasm for the collaboration and emphasized the breakthrough potential it holds for treating HER2-positive cancers. He highlighted the company’s dedication to advancing SNAP-CAR as a potential therapy for different solid tumors, including ovarian and breast cancer, as well as hematologic cancers.

The partnership with the University of Pittsburgh underscores Coeptis Therapeutics’ commitment to strategic collaborations with renowned academic institutions. By leveraging the university’s expertise and resources, Coeptis aims to accelerate the development of cutting-edge therapies and revolutionize the landscape of cancer treatment.

This sponsored research agreement represents a crucial milestone for Coeptis Therapeutics as it endeavors to develop its innovative cell therapy platforms to be at the forefront of cancer treatment. The collaboration with the University of Pittsburgh exemplifies the company’s unwavering pursuit of scientific excellence and strategic partnerships to improve patient outcomes.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) Bolsters Leadership Team with Appointment of Brian Cogley as Chief Financial Officer

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has made a significant announcement by appointing Brian Cogley as its new Chief Financial Officer (CFO). This strategic move reflects the company’s commitment to strengthening its leadership team with top talent. Cogley brings a wealth of experience in accounting and finance, making him a valuable addition to Coeptis.

With his extensive background in the industry and previous roles at leading firms, Cogley’s appointment as CFO signifies Coeptis’ dedication to enhancing its financial capabilities. As the company continues to focus on developing innovative cell therapy platforms for cancer treatment, Cogley’s expertise will play a vital role in supporting Coeptis’ growth and future success.

Coeptis Therapeutics recognizes the importance of strong financial leadership in driving the company’s strategic initiatives. By appointing Cogley as CFO, Coeptis aims to leverage his expertise to optimize financial operations, streamline processes, and enhance overall financial performance.

Cogley’s proven track record in financial management, strategic planning, and operational excellence aligns perfectly with Coeptis’ vision for success. His experience in the industry will provide valuable insights and contribute to the company’s continued growth trajectory.

Coeptis Therapeutics is excited to have Brian Cogley join their leadership team and looks forward to the positive impact his financial expertise will have on the company’s financial management and growth strategies. With Cogley’s appointment as CFO, Coeptis is well-positioned to achieve its goals and advance its mission of developing innovative cell therapy platforms for cancer treatment.

The appointment of Brian Cogley as Chief Financial Officer demonstrates Coeptis Therapeutics’ commitment to attracting top talent and building a strong foundation for future success. As the company continues to drive advancements in the field of cancer treatment, Cogley’s financial leadership will be instrumental in supporting Coeptis’ continued growth and innovation.

Meet the Exceptional Leadership Team at Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP): Driving Innovation in Biopharmaceuticals

iMetal Resources Inc. (OTCQB: IMRFF) (TSXV: IMR) is driven by a strong management team with extensive experience in a range of industries. The team, composed of professionals with expertise in geoscience, business development, and investor relations, is dedicated to advancing the company’s goals and maximizing shareholder value. Here are the key members of iMetal Resources’ management team and board of directors.

Dave Mehalick - Co-Founder, President & CEO

Mr. Mehalick is a successful executive with a career spanning over 30 years across various industries, including life sciences, technology, financial services, military contracting, entertainment, and consumer products. He has deep immersion in all facets of executive management, including mergers and acquisitions, corporate finance, C-Suite management, product development and licensing, partnerships, product commercialization, and corporate communications. Mr. Mehalick has assisted and managed several organizations towards successful company evolution resulting in significant transactions and financings. Currently, Mr. Mehalick is the Chairman, Chief Executive Officer, and President of Coeptis Therapeutics, leveraging his extensive experience to drive the company's growth.

Christine Sheehy - VP of Compliance and Corporate Secretary

Ms. Sheehy is a pharmaceutical business leader with over 25 years of experience, specializing in global commercialization of drug products and targeted therapeutics, including cell and gene therapies. Her previous roles include Senior Vice-President of Operations for Kadmon Pharmaceuticals and leading operational business at Three Rivers Pharmaceuticals. Ms. Sheehy has extensive experience in supply chain management, distribution, and international partnerships. She brings strategic thinking and leadership skills developed through working in start-ups and early-stage companies. Ms. Sheehy holds a bachelor's degree in accounting.

Dan Yerace - Director and Vice President of Operations

Mr. Yerace is a co-founder of Coeptis Pharmaceuticals and serves as the Vice President of Operations. With over ten years of experience in the pharmaceutical industry, Mr. Yerace is responsible for supply chain management, business development, portfolio management, and corporate strategy. His expertise spans procurement, global supply chain management, and operations. Prior to joining Coeptis, Mr. Yerace held leadership positions at Kadmon Pharmaceuticals. He holds a bachelor's degree in economics and an MBA.

Brian Cogley - Chief Financial Officer

Mr. Cogley is a senior-level financial executive with 15 years of experience in corporate finance and accounting across multiple industries, including life sciences, pharmaceuticals, financial services, and manufacturing. Prior to joining Coeptis Therapeutics, Mr. Cogley held various roles in finance and accounting, including as a Senior Manager in the Accounting Advisory practice at CFGI, LLC. He brings expertise in financial planning, reporting, asset and liability management, and strategic financial projects to his role as Chief Financial Officer. Mr. Cogley holds a bachelor's degree in accounting and an MBA with a concentration in finance.

Meet Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)'s Scientific Advisory Board

Evren Alici - M.D., PhD

Dr. Evren Alici is the Head of the Gene and Cell Therapy Group at the Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital. He is a senior researcher and group leader in Hematology, as well as the co-director of NextGenNK, an international Competence Center focused on the development of next-generation NK cell-based cancer immunotherapies. Dr. Alici obtained his M.D. and completed his residency at Ege University in Turkey. He earned his Ph.D. in 2006 at Karolinska Institutet. His research interests include generating universal cells, allogeneic NK cells, multiple myeloma, gene transfer, stem cell transplantation, and immunology. Dr. Alici has contributed to clinical studies with gene-modified cells in Sweden and has been involved in autologous NK cell therapy clinical trials.

Hans-Gustaf Ljunggren - M.D., PhD

Professor Hans-Gustaf Ljunggren is a renowned immunologist and former Dean of Research at Karolinska Institutet. He is the founder of the Center for Infectious Medicine and has made significant contributions in the field of infection medicine, immunology, and cancer research. Prof. Ljunggren earned his medical and doctoral degrees at Karolinska Institutet and currently serves as the Center Director of NextGenNK. With over 300 articles published and more than 40,000 citations, his expertise in immunology and infectious diseases is widely recognized. Prof. Ljunggren has participated in various international conferences, research evaluations, and advisory boards.

Arnika Kathleen Wagner - PhD., Assistant Professor

Dr. Arnika Kathleen Wagner is an Assistant Professor at the Department of Medicine, Huddinge, at Karolinska Institutet. Since 2019, her research has focused on NK cells in immunotherapy for Multiple Myeloma. Dr. Wagner completed her M.Sc. at the University of Lübeck, Germany, and pursued her Ph.D. studies under the supervision of Klas Kärre at Karolinska Institutet. Her research has centered around NK cells in mouse models for immunotherapy and the interaction of NK cells with other immune cells. Dr. Wagner's current work aims to advance the use of genetically modified NK cells in various immunotherapeutic approaches.


  • Source 1:
  • Source 2:
  • Source 3:
  • Source 4:
  • Source 5:
  • Source 6:
  • Source 7:
  • Source 8:
  • Source 9:×724.png
  • Source 10:
  • Source 11:
  • Source 12:
  • Source 13:
  • Source 14:
  • Source 15:



Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at

By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.

This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.

Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.

The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

Compensation: Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired by Lifewater Media LLC for a period beginning on 05/30/2023 and ending 06/02/2023 to publicly disseminate information about NASDAQ: COEP via digital communications. We have been paid fifteen thousand dollars USD.